1-戊基哌啶 | 10324-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-戊基哌啶
• 英文名称: 1-pentylpiperidine
• 英文别名: N-pentylpiperidine；N-n-amylpiperidine；1-Pentyl-piperidin
• CAS: 10324-58-0
• 化学式: C₁₀H₂₁N
• mdl: MFCD01700325
• 分子量: 155.283
• InChiKey: LQWJONARYDIOSE-UHFFFAOYSA-N

物化性质

• 沸点：
  198.2°C
• 密度：
  0.8282
• 保留指数：
  1122;1124;1129

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-戊基哌啶 在 铬 、 silica gel 、 镍 、 铜 、 sodium sulfate 作用下， 以43%的产率得到3-戊基吡啶
  参考文献：
  名称：

  Tereshko, A. B.; Tarasevich, V. A.; Kozlov, N. G., Russian Journal of Organic Chemistry, 1994, vol. 30, # 9.2, p. 1512

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N'-dipentyl-glutaramide 在 copper oxide-chromium oxide 作用下， 250.0 ℃ 、39.22 MPa 条件下， 生成 1-戊基哌啶
  参考文献：
  名称：

  Paden; Adkins, Journal of the American Chemical Society, 1936, vol. 58, p. 2493

  摘要：

  DOI：

文献信息

• Dibenzyl Amine Compounds and Derivatives
  申请人：Chang George

  公开号：US20070213371A1

  公开（公告）日：2007-09-13

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯基胺化合物及其衍生物，含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物，包括人类。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• Silicon Polonovski Reaction. Formation and Synthetic Application of α-Siloxy Amines
  作者：Norihiro Tokitoh、Renji Okazaki

  DOI：10.1246/bcsj.60.3291

  日期：1987.9

  amines with acyl halides and haloformates gave the corresponding amides and carbamates in moderate to good yields, respectively. Treatment of α-siloxy amines with acetic acid resulted in a direct dealkylation to free secondary amines. Fluoride induced alkylation of α-siloxy amines using alkyl halides as electrophiles leading to tertiary amines was also examined and demonstrated to be a new transalkylation

  通过用三烷基甲硅烷基三氟甲磺酸酯处理叔胺 N-氧化物获得的甲硅烷氧基铵盐的碱促进重排，原位制备了一种新的多功能合成中间体 α-甲硅烷氧基胺。发现碱和甲硅烷基化试剂的最佳组合是甲基锂和叔丁基二甲基甲硅烷基三氟甲磺酸酯。α-甲硅烷氧基胺与酰卤和卤代甲酸酯的反应分别以中等至良好的产率得到相应的酰胺和氨基甲酸酯。用乙酸处理 α-甲硅烷氧基胺导致直接脱烷基化为游离仲胺。还研究了氟化物诱导的α-甲硅烷氧基胺的烷基化，使用烷基卤作为亲电试剂产生叔胺，并证明是一种新的胺烷基转移方法。
• Aryl and biaryl piperidines with MCH modulatory activity
  申请人：PHARMACOPEIA, INC.

  公开号：US20030013720A1

  公开（公告）日：2003-01-16

  In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown below: 1

  在一个实施例中，这项发明提供了一类新型化合物，作为MCH受体的拮抗剂，包括制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及治疗、预防或改善与MCH受体相关的一种或多种疾病的方法。下面展示了一个说明性的创新化合物： 1
• [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES<br/>[FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005085226A1

  公开（公告）日：2005-09-15

  The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (Formula (I)). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper­triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.

  本发明涉及新颖的芳基哌啶或哌嗪化合物，其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途（公式（I））。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。

表征谱图